For some reason all reverse splits are always taken as negative. One reason may be that it demonstrates that the company does not believe it will achieve the pps necessary to get relisted on the exchange anytime soon without the reverse split. Anyway, I do think the company has a bright future and the share price will recover over time based on so many opportunities for the company to achieve good financial results as the clinical trials come to successful conclusions. This is a good buying opportunity for those with dry powder.
Recent AGEN News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 09:04:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 12:52:03 PM
- Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development • Business Wire • 05/11/2026 12:45:00 PM
- Agenus to Provide First Quarter 2026 Financial Report and Corporate Update • Business Wire • 05/04/2026 08:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 08:35:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 08:34:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:15:02 PM
- アジーナス、BOT+BALアクセスプログラムの独占的グローバルパートナーにBAP Pharmaを指名 • Business Wire • 04/22/2026 03:56:00 PM
- Agenus ernennt BAP Pharma zum exklusiven globalen Partner für die BOT+BAL-Zugangsprogramme • Business Wire • 04/22/2026 12:55:00 AM
- Agenus désigne BAP Pharma comme partenaire mondial exclusif pour les programmes d’accès à la combinaison BOT+BAL • Business Wire • 04/22/2026 12:55:00 AM
- Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 • Business Wire • 04/21/2026 02:00:00 PM
- Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs • Business Wire • 04/21/2026 12:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/20/2026 09:21:47 PM
- Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer • Business Wire • 04/17/2026 08:43:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 08:15:10 PM
- Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 • Business Wire • 04/03/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:29 PM
- アジーナス、MSSまたはpMMRの転移性大腸がんを対象としたBOT+BAL免疫療法併用のグローバル第3相BATTMAN試験で初の患者登録を発表 • Business Wire • 04/02/2026 04:31:00 AM
- Agenus annonce le recrutement du premier patient dans l’essai mondial de phase III BATTMAN portant sur l’association immunothérapeutique BOT+BAL dans le cadre du cancer colorectal métastatique MSS ou pMMR • Business Wire • 04/02/2026 04:27:00 AM
